Skip to content

Total implantable venous access port related thrombosis risk assessment and clinical efficacy study of perioperative drug preventive anticoagulation

Total implantable venous access port related thrombosis risk assessment and clinical efficacy study of perioperative drug preventive anticoagulation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048754
Enrollment
Unknown
Registered
2021-07-16
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-related thrombosis

Interventions

test group1:First make the chest wall pocket, then insert the catheter
test group 2:Insert the catheter first, then make the chest wall pocket
control group 1:The chest wall pocket is made first, and then the catheter is inserted. It is not anticoagulant
control group 2:Insert the catheter first, then make the chest wall pocket, it is not anticoagulant

Sponsors

Affiliated Tumor Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with various tumors confirmed by clinical diagnosis, cytology or histopathological examination; 2. Long-term and repeated intravenous chemotherapy needs to be performed using an infusion port; 3. Karnofsky score >= 80 points; 4. Expected survival > 6 months; 5. Aged >=18 years old; 6.CrCl>70ml/min; 7. Patients without mental illness; 8. Understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. The puncture site has received radiotherapy or severe vascular deformation; 2. Puncture catheter path vein through the vascular surgery site; 3. Patients who have installed cardiac pacemakers or have undergone cardiac surgery; 4. Patients with a history of acute thrombosis or subclavian vein and superior vena cava occlusion; 5. Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
VTE incidence;

Countries

China

Contacts

Public ContactDeng Guoyu

Affiliated Tumor Hospital of Guangxi Medical University

345240874@qq.com+86 18878980987

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026